ICER: FDA failed to protect patients from unproven Alzheimer's treatment with known harms
Published
(Natural News) The Food and Drug Administration (FDA) drew criticisms after granting Alzheimer’s disease drug Aduhelm a conditional approval. It allows the drug scientifically known as aducanumab to be prescribed and used while its maker Biogen conducts a post-marketing, phase 4 confirmatory study that could take years to complete. Aduhelm is the first Alzheimer’s medication...
Full Article